Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carrier State Clear all
Completed No phase listed Observational

Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID

NCT00006335
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
13 Years to 17 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis

NCT00620984
View directory record Official record
Conditions
Mastitis, Staphylococcus Aureus, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older · Female only
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

NCT01506609
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Placebo, Veliparib, Carboplatin, Temozolomide, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans

NCT00017732
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

NCT02314156
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
West Hollywood, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Jul 21, 2026, 6:54 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

NCT04670965
View directory record Official record
Conditions
Bone Loss
Interventions
E-PRF/rhBMP-2 (similar ratios), E-PRF/ACS/rhBMP-2, rhBMP-2/E-PRF, E-PRF only
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

NCT00535119
View directory record Official record
Conditions
Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey

NCT01398813
View directory record Official record
Conditions
Hypohidrotic Ectodermal Dysplasia, X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations

NCT00302146
View directory record Official record
Conditions
Parkinson Disease, Gaucher Disease
Interventions
15-0 H20
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk

NCT00735150
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
questionnaire, interview
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2010 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG

NCT01730417
View directory record Official record
Conditions
Neuroendocrine Tumors, Heart Failure
Interventions
no carrier added metaiodobenzylguanidine
Drug
Lead sponsor
Bennett Chin
Other
Eligibility
21 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Jul 21, 2026, 6:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hemophilia A Research Program

NCT07414511
View directory record Official record
Conditions
Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII), FVIII Deficiency, Carrier of Hemophilia A, Inhibitors, Pregnancy, Maternal Blood Loss, Pregnancy Complications, Bleeding Disorder, Hemorrhage, Postpartum, Alloimmunization, X-Linked
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

NCT05132907
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
HDT-301
Biological
Lead sponsor
HDT Bio
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

NCT00986206
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
Biomarker LPA and HE4
Diagnostic Test
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736
View directory record Official record
Conditions
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

NCT00575055
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
186
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jul 21, 2026, 6:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Aquagenic Wrinkling Prediction

NCT06831110
View directory record Official record
Conditions
Aquagenic Wrinkling of Palms, Carrier State
Interventions
Aquagenic Wrinkling
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 24 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Not applicable Interventional

An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection

NCT00000647
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG, Zidovudine, Interferon alfa-n1, Peripheral lymphocyte infusion, Bone marrow transplant
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jul 21, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Study of Oxycyte in Severe Closed Head Injury

NCT00174980
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Oxycyte
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

NCT03619798
View directory record Official record
Conditions
Diagnoses Disease
Interventions
HemoTypeSC
Device
Lead sponsor
Silver Lake Research Corporation
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 21, 2026, 6:54 AM EDT
Active, not recruiting Phase 1 Interventional

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

NCT02208375
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 6:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Monitoring in TP53 Mutation Carriers

NCT02289326
View directory record Official record
Conditions
Li-Fraumeni Syndrome, Hereditary Cancer Syndromes, TP53 Gene Germline Mutation Carrier
Interventions
Not listed
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 21, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

NCT00000663
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 5 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

NCT04690348
View directory record Official record
Conditions
Recurrent Brain Metastases
Interventions
Craniotomy, Cesium-131 brachytherapy
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 6:54 AM EDT